Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. (Q54712992)

3 June 2018

title

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. (English)

1 reference

3 June 2018

main subject

lymphocyte

0 references

phase II clinical trial

0 references

1 reference

10

John C Byrd

1 reference

3 June 2018

Thomas S Lin

1

1 reference

3 June 2018

Louie Naumovski

2

1 reference

3 June 2018

Philip S Lecane

3

1 reference

3 June 2018

Margaret S Lucas

4

1 reference

3 June 2018

Mollie E Moran

5

1 reference

3 June 2018

Carolyn Cheney

6

1 reference

3 June 2018

David M Lucas

7

1 reference

3 June 2018

See-Chun Phan

8

1 reference

3 June 2018

Richard A Miller

9

1 reference

3 June 2018

publication date

1 December 2009

1 reference

3 June 2018

published in

Leukemia & Lymphoma

1 reference

3 June 2018

volume

50

1 reference

3 June 2018

issue

12

1 reference

3 June 2018

page(s)

1977-1982

1 reference

3 June 2018

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288464

10.3109/10428190903288464

21 January 2018

Identifiers

DOI

1 reference

3 June 2018

PubMed ID

19860624

1 reference

3 June 2018